VDX-111, a novel small molecule, induces necroptosis to inhibit ovarian cancer progression

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Epithelial ovarian cancer, particularly recurrent and platinum-resistant forms, presents limited treatment avenues.
• Nonhomologous recombination deficient cancers also face therapeutic challenges.
• Identifying novel therapeutic agents is crucial for improving patient outcomes.

Purpose of the Study:

• To elucidate the mechanism of action of the small molecule VDX-111.
• To evaluate the therapeutic potential of VDX-111 in ovarian cancer models.
• To investigate VDX-111's efficacy in BRCA wild-type ovarian cancer cell lines.

Main Methods:

• Cell viability assays were performed on ovarian cancer cell lines treated with VDX-111.
• Reverse phase protein array (RPPA) analysis identified VDX-111-induced signaling pathway alterations.
• Immunoblots, Incucyte live cell imaging, and Annexin/PI assays assessed cell death mechanisms.
• In vivo efficacy was tested using patient-derived xenograft and syngeneic murine models.

Main Results:

• VDX-111 demonstrated dose-dependent cytotoxicity across ovarian cancer cell lines.
• RPPA and immunoblot analyses revealed VDX-111 modulates signaling pathways related to autophagy and necroptosis.
• Cell death was predominantly nonapoptotic and dependent on necroptosis, as indicated by necrostatin-1 treatment.
• VDX-111 inhibited tumor growth in both patient-derived xenograft and syngeneic murine models.

Conclusions:

• VDX-111 exhibits potent anti-ovarian cancer activity through a necroptosis-dependent mechanism.
• The compound shows therapeutic potential for platinum-resistant and BRCA wild-type ovarian cancers.
• VDX-111 may also stimulate an antitumor immune response, warranting further investigation.